Future Perfect: Opportunities and Obstacles for HIV Vaccines


The HIV vaccine research field has evolved tremendously since the RV144 clinical trial first demonstrated empirical evidence that a vaccine could prevent HIV transmission. Innovative prevention modalities such as microbicides, PrEP, long-lasting ARV, and monoclonal antibody injectables are providing novel tools for prevention. Still, the pandemic continues to impose tremendous morbidity, mortality, and economic burden across the globe. So where are we now? What are the most promising opportunities and where do obstacles remain along the pathway to an HIV vaccine?

The Global HIV Vaccine Enterprise in collaboration with AVAC, Bill & Melinda Gates Foundation, Imperial College London, INSERM, MHRP, and NIH convened the satellite session “Future Perfect: Opportunities and Obstacles for HIV Vaccines” at the 9th IAS Conference on HIV Science (IAS 2017) in Paris, France.

“Future Perfect” explored the latest in HIV vaccine design, development, and testing, with a focus on current trials on an efficacy pathway and promising approaches in pre- or early clinical trials. Three state-of-the-art presentations on the vaccine pipeline, including passive immunization, promising vector-platforms, and the development of envelope proteins able to elicit broadly neutralizing antibodies were followed by a moderated discussion on the scientific priorities, challenges, and opportunities for next generation vaccines.

Date: 23 July, 2017
Time: 5:00 PM — 7:00 PM


Carl Dieffenbach, National Institutes of Health (NIH)
Yves Levy, French National Institute of Health and Medical Research (INSERM)
Nelson Michael, Military HIV Research Program (MHRP)
Nina Russell, Bill & Melinda Gates Foundation (BMGF)
Gabriella Scarlatti, Global HIV Vaccine Enterprise
Robin Shattock, Imperial College London
Mitchell Warren, AVAC

If you have any questions about the meeting, please contact Gabriella Scarlatti at

Global HIV Vaccine Enterprise, 64 Beaver Street, # 352, New York, NY 10004 | +1 212-461-3692 or toll free at +1-866-966-4483
All Content ©2005 - 2013 Global HIV Vaccine Enterprise   |   Terms of Use   |   Privacy Policy   |   Log In / My Account